Context Therapeutics (CNTX) Stock Price, Quote, News & History

Comments

Context Therapeutics Inc (CNTX) Stock Price, Quote, News & History

CNTXNASDAQ

Trade with Public

$3.36

0.278.74%

At close: Mar 13, 5:00 PM EST

$3.32

-0.04-1.19%

After Hours: 7:59 PM EST

OverviewNews Earnings Analyst Ratings Insider Trades Short Interest Stock Report

Key Statistics

Open

$3.13

Close

$3.36

Volume / Avg.

1.77M / 1.58M

Day Range

$3.11 - $3.44

52 Wk Range

0.49 - 3.30

Market Cap

$305.04M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

1.51%

Days to Cover

1.83

Recent Context Therapeutics Inc News

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga Insights

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-22.35M

Investing Cash Flow (TTM)

-33.95K

Financing Cash Flow (TTM)

14.52M

Free Cash Flow (TTM)

-22.38M

Capital Expenditure (TTM)

-33.95K

Net Change in Cash (TTM)

-7.86M

Analyst Trends and Forecast

1

Sep 25

2

Oct 25

2

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$232.38M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.89

Earnings Yield % (TTM)

-7.75%

Earnings Yield % (FWD)

-6.79%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.80

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$76.94M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.13

Close

$3.36

Volume / Avg.

1.77M / 1.58M

Day Range

$3.11 - $3.44

52 Wk Range

0.49 - 3.30

Market Cap

$305.04M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

1.51%

Days to Cover

1.83

About

Sector

Health Care

Industry

Pharmaceuticals

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, includin...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Context Therapeutics (CNTX) stock?

A

You can purchase shares of Context Therapeutics (NASDAQ:CNTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Context Therapeutics (CNTX) competitors?

A

Other companies in Context Therapeutics’s space includes: Atea Pharmaceuticals Inc (NASDAQ:AVIR), MediWound Ltd (NASDAQ:MDWD), SNDL Inc (NASDAQ:SNDL), NervGen Pharma Corp (NASDAQ:NGEN) and Aquestive Therapeutics Inc (NASDAQ:AQST).

Q

What is the forecast, or price target, for Context Therapeutics (CNTX) stock?

A

Context Therapeutics has a consensus price target of $6.06.

Q

What is the current price for Context Therapeutics (CNTX)?

A

The stock price for Context Therapeutics (NASDAQ: CNTX) is $3.32 last updated March 13, 2026 at 7:59 PM EDT.

Q

Does Context Therapeutics (CNTX) pay a dividend?

A

There are no upcoming dividends for Context Therapeutics.

Q

When is Context Therapeutics (NASDAQ:CNTX) reporting earnings?

A

Context Therapeutics does not have any upcoming earnings scheduled.

Q

Is Context Therapeutics (CNTX) going to split?

A

There is no upcoming split for Context Therapeutics.

Q

What sector and industry does Context Therapeutics (CNTX) operate in?

A

Context Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

People Also Watch

Atea Pharmaceuticals Inc

Aquestive Therapeutics Inc

SIGA Technologies Inc

Key Statistics

Open

$3.13

Close

$3.36

Volume / Avg.

1.77M / 1.58M

Day Range

$3.11 - $3.44

52 Wk Range

0.49 - 3.30

Market Cap

$305.04M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

1.51%

Days to Cover

1.83

Recent Context Therapeutics Inc News

12 Health Care Stocks Moving In Monday's Pre-Market Session

Benzinga Insights

PRO
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.

Benzinga Newsdesk

PRO
Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-22.35M

Investing Cash Flow (TTM)

-33.95K

Financing Cash Flow (TTM)

14.52M

Free Cash Flow (TTM)

-22.38M

Capital Expenditure (TTM)

-33.95K

Net Change in Cash (TTM)

-7.86M

Analyst Trends and Forecast

1

Sep 25

2

Oct 25

2

Nov 25

1

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$232.38M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.89

Earnings Yield % (TTM)

-7.75%

Earnings Yield % (FWD)

-6.79%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.80

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$76.94M

Debt to Equity

0.00

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.13

Close

$3.36

Volume / Avg.

1.77M / 1.58M

Day Range

$3.11 - $3.44

52 Wk Range

0.49 - 3.30

Market Cap

$305.04M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

72

Short Interest

1.51%

Days to Cover

1.83

About

Sector

Health Care

Industry

Pharmaceuticals

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, includin...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry